SOPHiA DDM™ Solid Tumor Solutions

Profiling the cancer genome to optimize solid tumor management

Clinical oncology is increasingly adopting next-generation sequencing (NGS) in response to the growing number and type of biomarkers that require rapid assessment.

Targeted genomic profiling offers the ability to focus on a set of biomarkers known to be associated with a cancer. Compared to broader approaches, targeted gene sequencing reduces workflow complexity, avoids unnecessary sequencing costs, and minimizes the effort needed for variant interpretation and reporting.

Expertly designed panels, delivering a high on-target rate throughout the entire target regions

Ready-to-use target-enriched libraries generated in just 1.5 days for DNA and 6 hours for RNA

Customizable content to perfectly meet the unique needs of each research laboratory

High coverage uniformity, ensuring accurate variant detection (SNVs, Indels, CNV, MSI, and gene fusions) and unlocking the efficiency in multiplexing more samples per run

Streamline interpretation with the SOPHiA DDM™ Platform intuitive variant filters, algorithm-supported variant classification with OncoPortal™ Plus to obtain the latest scientific evidence on all the relevant variants​

Have access to one of the largest networks of connected healthcare institutions within SOPHiA DDM™ Platform, to gain and share knowledge on relevant variants​

    pink dots icon

    Product Details

    Unlock efficiency in multiplexing more samples per run​

    SOPHiA DDM™ Solid Tumor Solution (STS) and Solid Tumor Plus Solution (STS+) are NGS-based applications that combine expertly designed targeted panels with access to the analysis and interpretation functions of the SOPHiA DDM™ Platform. Both solutions enable accurate detection of SNVs, Indels and CNVs in addition to Microsatellite Instability (MSI) status in genes involved in solid tumors, such as lung, colorectal, skin, and brain cancers. SOPHiA DDM™ STS+ offers additional insights by also targeting 136 gene fusions, MET (exon 14 skipping), and EGFR (vIII exon skipping). Both solutions provide a streamlined sample-to-report workflow that greatly accelerates variant assessment, while ensuring confidence in your results.

    Sophia Tumor Solutions Plus Screenshot
    Sophia Tumor Solutions Shower

    Dedicated features to ease variant interpretation

    The SOPHiA DDM™ Platform features intuitive variant filters and prioritization options to streamline interpretation and help reduce turnaround time.

    • Hotspot Screening to quickly pinpoint the relevant hotspots and provide a clear overview of the wild-type hotspot positions
    • Variant Pre-Classification to facilitate assessment of variants’ pathogenicity
    • Virtual Panels to limit interpretation to a subset of genes
    • Cascading Filters to enable user-created custom filtering strategies for quicker identification of relevant variants
    • OncoPortal™ Plus to support decisions based on the JAX-CKB, CAP, ASCO, AMP and other databases

    Thoroughly assessed to provide confidence in your results

    A six-center evaluation assessed SOPHiA DDM™ STS with more than 150 samples. The study confirmed reliable performance that can facilitate confident decision-making.

    Performance Metrics Observed Lower CI
    Analytical Sensitivity 98.77% 93.31%
    Analytical Precision 100% 96.25%
    Analytical Specificity 100% 99.92%
    Analytical Accuracy 99.97% 99.85%
    Analytical Repeatability 96.45% 96.41%
    Analytical Reproducibility 89.13% 89.05%
    Coverage Uniformity 98.7% 92.5%

    Values have been calculated for SNVs and Indels from a total of 150 samples processed on MiSeq®.

    Sophia Tumor Solutions Workflow
    pink dots icon


    Parameters SOPHiA DDM™ STS SOPHiA DDM™ STS+
    Diseases Covered Lung, colorectal, skin, and brain cancers Lung, colorectal, skin, and brain cancers
    Gene Symbols Covered 42 genes DNA panel: 42 genes:
    RNA panel: 136 gene fusions, MET (exon 14 skipping), and EGFR (vIII exon skipping).
    Target Region Size 22 Kb 22 Kb
    Key Biomarkers ALK, BRAF, EGFR, IDH1, IDH2, GNA11, GNAS, GNAQ, HIST1H3B, H3F3A, H3F3B, MET, KRAS, KIT, NRAS, MET, PIK3CA Same biomarkers of SOPHiA DDM™ STS and fusion events involving genes such as ALK, BRAF, EGFR, FGFR1, FGFR2,
    Sample Type FFPE, fresh-frozen tissue FFPE, fresh-frozen tissue
    Input Amount 10 ng DNA minimum (50 ng recommended) 10 ng DNA minimum (50 ng recommended), 100-200 ng RNA
    Sequencer Compatibility
    • Illumina MiniSeq™ kit  (2x150bp)
    • Illumina MiSeq® kit v3 (2x300bp)
    • Ion Torrent™ Ion (S5)
    • MGI DNBSEQ-G400
    • Illumina MiSeq® kit v3(2x300bp)
    • Illumina NextSeq® 500/550 V2 (2x150bp)
    Library Preparation Time 1.5 days for DNA 1.5 days for DNA, 6 hours for RNA
    Analysis Time From FASTQ From 4 hours From 4 hours
    Detected Variants
    • SNVs
    • Indels
    • CNV in 24 genes
    • MSI
    • SNVs
    • Indels
    • CNV in 24 genes
    • MSI
    • Fusions
    pink dots icon

    Contact us

    Please fill out the form below to get in touch

    pink dots icon

    Related products

    SOPHiA DDM™ for Blood Cancers

    Our future-proof end-to-end solutions allow detection and characterization of complex genomic variants associated with different blood cancers.

    SOPHiA DDM™ For Blood Cancers

    SOPHiA DDM™ for Solid  Tumors

    From targeted to comprehensive genomic profiling, our solutions support healthcare professionals in their journey to analyze solid tumors.   

    SOPHiA DDM™ For Solid Tumors

    SOPHiA DDM™ for Hereditary Cancers

    Our solutions help reduce time to confidently assess multiple types of challenging genetic variants that indicate predisposition to inherited cancers.

    SOPHiA DDM™ For Hereditary Cancers